Review Article

COVID-19: Recent Updates on its Mechanism and Treatment

Pranali R. Gajbhiye*, Yogesh N. Gholse, Rahul H. Kasliwal, Karishma D. Kamde, Kajal L. Bisane, Dinesh R. Chaple
Priyadarshini J. L. College of Pharmacy, Electronic Zone Building, MIDC, Hingna Road, Nagpur-440016, Maharashtra, India.
***Corresponding author's E-mail:** pranaligajbhiye21@gmail.com

Received: 10-03-2020; **Revised:** 20-05-2020; **Accepted:** 26-05-2020.

ABSTRACT

Toward the finish of 2019 a novel infection, serious intense respiratory condition coronavirus 2 (SARS-CoV-2), causing extreme intense respiratory disorder extended all inclusive from Wuhan, China. In March 2020 the World Health Organization announced the SARS-Cov-2 infection a worldwide pandemic. We played out an account audit to depict existing writing with respect to Coronavirus Disease 2019 (COVID-19) the study of disease transmission, pathophysiology, finding, the executives and future point of view. MEDLINE, EMBASE and Scopus databases were scanned for important articles. Albeit just when the pandemic finishes it will be conceivable to evaluate the full wellbeing, social and financial effect of this worldwide fiasco, this survey speaks to an image of the present best in class. Specifically, we center around general wellbeing sway, pathophysiology and clinical appearances, analysis, case the executives, crisis reaction and readiness. This audit expects to sum up early findings on the study of disease transmission, clinical highlights, analysis, treatment, the executives, and anticipation of COVID-19.

Keywords: COVID-19, epidemiology, mechanism and treatment, prevention.

INTRODUCTION

In mid 2020, another infection started creating features everywhere throughout the world in view of the remarkable speed of its transmission. From its starting points in a nourishment advertise in Wuhan, China, in December 2019 to nations as distant the United States and the Philippines, the infection (authoritatively named SARS-CoV-2) has influenced several thousands, with a rising loss of life now more than 17,000. The ailment brought about by a contamination with SARS-CoV-2 is called COVID-19, which represents coronavirus infection 2019.

Figure 1: COVID-19

Coronavirus (CoV) is a huge group of positive-sense, single-abandoned RNA infections that have a place with the Nidovirales request. The request incorporates Roniviridae, Arteriviridae, and Coronaviridae families. The Coronaviridae family is partitioned into Torovirinae and Coronavirinae subfamilies. Coronavirinae is further sub arranged into alpha-, beta-, gamma-, and delta COVs.[1] Phylogenetic grouping represents the characterization of these subtypes of infections. Their viral RNA genome ranges from 26 to 32 kilo bases long. They can be detached from various creature species. These incorporate feathered creatures, domesticated animals, and warm blooded creatures, for example, camels, bats, veiled palm civets, mice, hounds, and cats.[2] The across the board appropriation and infectivity of COV make it a significant pathogen.

An infection has a characteristic and zoonotic starting point: two situations that can conceivably clarify the cause of SARS-CoV2 are: (I) common choice in a creature have before zoonotic exchange; and (ii) regular determination in people following zoonotic transfer.[3] Clinical highlights and hazard factors are profoundly factor, making the clinical seriousness go from asymptomatic to fatal.[4] Comprehension of COVID-19 is on-going.

This audit expects to sum up early findings on the study of disease transmission, clinical highlights, analysis, treatment, the executives, and anticipation of COVID-19.

Pathophysiology and Clinical Manifestation

To address the pathogenetic components of SARS-CoV-2, its viral structure and genome must be thought of. Coronaviruses are encompassed positive strand RNA infections with the biggest known RNA genomes—30–32 kb—with a 50-top structure and 30-poly-A tail. Beginning from the viral RNA, the union of polyprotein 1a/1ab (pp1a/pp1ab) in the host is realized.[5] The interpretation works through the replication-translation complex (RCT) composed in twofold film vesicles and by means of the combination of subgenomic RNAs (sgRNAs) arrangements. Of note, translation end happens at

interpretation administrative successions, situated between the purported open understanding edges (ORFs) that function as formats for the creation of subgenomicm RNAs.[6] In the atypical CoV genome, atleast six ORF examine be available. Among these, an edge move somewhere in the range of ORF1a and ORF1b guides the creation of both pp1a and pp1ab polypeptides that are prepared by virally encoded chymotrypsin-likeprotease (3CLpro) or primary protease (Mpro), just as a couple of papain-like proteases for delivering 16 non-auxiliary proteins (nsps). Aside from ORF1a and ORF1b, different ORFs encode for auxiliary proteins, including spike, film, envelope, and nucleocapsid proteins and adornment proteic chains. Different CoVs present extraordinary auxiliary and get to or yprotein stranslated by committed sgRNAs. Pathophysiology and harmfulness components of CoVs, and in this way likewise of SARS-CoV-2 have connections to the capacity of then sps and auxiliary proteins. For example, investigate has under lined that nsps can obstruct the host natural immuneresponse. Among the elements of the auxiliary proteins, the envelope has an essential job in infection pathogenicity as it advances viral gathering and release.[4]

The pathogenic instrument that produces pneumonia is by all accounts especially mind boggling. The information so far accessible appear to demonstrate that the viral contamination is fit for delivering an unnecessary insusceptible response in the host. At times, a response happens, which overall is named a "cytokine storm". The effect is broad tissue harm. The hero of this tempest is interleukin 6 (IL-6). IL-6 is delivered by enacted leukocytes and follows up on an enormous number of cells and tissues.[7] It can advance the differentiation of B lymphocytes, advances the development of certain classifications of cells, and restrains the development of others. It likewise animates the creation of intense stage proteins and assumes a significant job in thermoregulation, in bone support and in the usefulness of the focal anxious system.[8] In spite of the fact that the principle pretended by IL-6 is ace inflammatory, it can likewise have hostile to inflammatory effects. Thus, IL-6 increments during inflammatory ailments, contaminations, immune system issue, cardiovascular ailments and a few kinds of cancer.[9] It is likewise ensnared into the pathogenesis of the cytokine discharge disorder (CRS) that is an intense foundational inflammatory condition portrayed by fever and different organ dysfunction.[10] The infection may go through the mucous layers, particularly nasal and larynx mucosa, at that point enters the lungs through the respiratory tract. At that point the infection would assault the focusing on organs that express angiotensin changing over catalyst 2 (ACE2, for example, the lungs, heart, renal framework and gastrointestinal tract. The infection starts a subsequent assault, making the patient's condition bother around 7 to 14 days after beginning. B lymphocyte decrease may happen right off the bat in the malady, which may affect neutralizer creation in the patient. In addition, the inflammatory factors related with infections for the most part containing IL-6 were significantly expanded, which likewise added to the disturbance of the malady around 2 to 10 days after beginning. The clinical range of COVID-19 differs from asymptomatic or pauci indicative structures to clinical conditions portrayed by extreme respiratory disappointment that requires mechanical ventilation and backing in an emergency unit), (to multi organ and foundational signs as far as sepsis, septic stun, and different organ brokenness disorder (MODS).[11]

Symptoms of COVID-19:

The symptoms of COVID-19 disease show up after a hatching time of around 5.2 days. The period from the beginning of COVID-19 indications to death ran from 6 to 41 days with a middle of 14 days. This period is subject to the age of the patient and status of the patient's insusceptible framework. It was shorter among patients >70-years old contrasted and those under the time of 70. Some normal side effects that have been explicitly connected to COVID-19 include:

- Shortness of breath
- Having a hack that gets progressively serious after some time
- A second rate fever that bit by bit increments in temperature
- Trouble relaxing
- Blue lips or face
- Persistent agony or weight in the chest
- Confusion
- Excessive sluggishness



Figure 2: Common symptoms and potential complication

Treatment and Management

Specialists recently used to treat SARS and MERS are potential possibility to treat covid-19. Different specialists with clear in vitro movement against SARS-COV and MERS-COV were utilized during the SARS and MERS episodes, with conflicting viability. Meta-investigations of

SARS and MERS treatment examines found no away from of a particular regimen.[12] Underneath, the in vitro movement and distributed clinical encounters of probably the most encouraging repurposed drugs for COVID-19 are explored.

Chloroquine and Hydroxychloroquine

Chloroquine and hydroxychloroquine have along-standing history in the avoidance and treatment of intestinal sickness and the treatment of interminable fiery infections including foundational lupus erythematosus (SLE) and rheumatoid joint pain (RA).[13] Chloroquine and hydroxychloroquine seem to square popular passage into cells by restraining glycosylation of host receptors, proteolytic preparing, and endosomal fermentation. These operators likewise have immunomodulatory impacts through constriction of cytokine creation and hindrance of autophagy and lysosomal action in have cells.[14] Chloroquine represses SARS-CoV-2 in vitro with a half-maximal viable fixation (EC50) in the low micromoler run. Hydroxychloroquine has in vitro movement with a lower EC50 for SARS-CoV-2 contrasted and chloroquine following 24 hours of development (hydroxychloroquine: EC50 =6.14µm and chloroquine: EC50 =23.90µm).[15]

No excellent proof exists for the adequacy of chloroquine/hydroxychloroquine treatment of SARS or MERS. A news preparation from China announced chloroquine was effectively used to treat a progression of more than 100 COVID-19 cases bringing about improved radiologic discoveries, upgraded viral leeway, and diminished illness progression.[16] Be that as it may, the clinical preliminary plan and results information have not yet been introduced or distributed for peer survey, forestalling approval of these cases. Arecentopen-name non randomized French investigation of 36 patients (20 in the hydroxychloroquine gathering and 16 in the benchmark group) revealed improved virologic freedom with hydroxychloroquine, 200mg, by mouth at regular intervals contrasted and control patients getting standard steady care.Virologic leeway at day 6, estimated by nasopharyngeal swabs, was 70% (14/20) versus 12.5% (2/16) for the hydroxychloroquine and control gatherings, individually (P = .001). The creators additionally announced that option of azithromycin to hydroxychloroquine in 6 patients brought about numerically prevalent viral leeway (6/6,100%) contrasted and hydroxychloroquine monotherapy (8/14, 57%).[17]

Dosing of chloroquine to treat COVID-19 has comprised of 500mg orally a few times day by day. Hydroxychloroquine dosing proposals for SLE for the most part are 400mg orally every day. Notwithstanding, a physiologically based pharmacokinetic demonstrating study suggested that the ideal dosing routine for hydroxychloroquine in COVID-19 treatment is a stacking portion of 400mg twice day by day for 1 day followed by 200mg twice day by day. Interestingly, elective proposals are made for 600mg all out every day portion dependent on wellbeing and clinical experience for Whipple disease.[18] Further investigations are expected to outline the ideal portion for COVID-19.

Chloroquine and hydroxychloroquine are moderately very much endured as shown by broad involvement with patients with SLE and intestinal sickness. Be that as it may, the two specialists can cause uncommon and genuine antagonistic impacts (<10%), including QTc prolongation, hypoglycemia, neuropsychiatric impacts, and retinopathy. Pattern electrocardiography to assess for delayed QTc is prudent preceding and following inception of these drugs in light of the potential for arrhythmias, particularly in fundamentally sick patients and those taking attendant QT-interim drawing out prescriptions, for example, azithromycin and fluoroquinolones. No critical unfavorable impacts have been accounted for chloroquine at the dosages and lengths proposed for COVID-19. Utilization of chloroquine and hydroxychloroquine in pregnancy is commonly viewed as sheltered. A survey of 12 examinations including 588 patients getting chloroquine or hydroxychloroquine during pregnancy found no over baby visual toxicity.[19]

Ribavirin

Ribavirin, a guanine simple, restrains viral RNA-subordinate RNA polymerase. Its action against different nCoVs makes it a contender for COVID-19 treatment. Be that as it may, its in vitro action against SARS CoV was restricted and required high focuses to repress viral replication, requiring high-portion (eg, 1.2g to 2.4g orally at regular intervals) and mix treatment. Patients got either intravenous or enteral organization in past investigations. No proof exists for breathed in ribavirin for nCoV treatment, and information with respiratory syncytial infection propose breathed in organization offers no advantage over enteral or intravenous organization. Asystematic audit of the clinical involvement in ribavirin for the treatment of SARS uncovered in definitive outcomes in 26 of the 30 investigations explored, with 4 examinations exhibiting conceivable damage because of unfavorable impacts including hematologic and liver toxicity.37 In the treatment of MERS, ribavirin, by and large in mix with interferons, showed no perceivable impact on clinical results or viral clearance.[20] A scarcity of clinical information with ribavirin for SARSCoV-2 methods its restorative job must be extrapolated from other nCoV information.

Ribavirin causes extreme portion subordinate hematologictoxicity. The high dosages utilized in the SARS preliminaries came about in hemolyticanemia in over 60% of patients. Comparable security concerns were found in the biggest MERS observational preliminary, with roughly 40% of patients taking ribavirin in addition to interferon requiring blood transfusions. 75% of patients taking ribavirin for SARS experienced transaminase rises. Ribavirin is likewise a known teratogen and contraindicated in pregnancy.[21]

The uncertain viability information with ribavirin for different nCoVs and its generous poisonousness recommend that it has restricted an incentive for treatment of COVID-19.

Lopinavir/Ritonavir

Lopinavir/ritonavir, a US Food and Drug Administration (FDA)- affirmed oral blend specialist for treating HIV, exhibited in vitro action against other novel coronaviruses by means of restraint of 3-chymotrypsin-likeprotease.[22]

A methodical audit of lopinavir/ritonavir for the treatment of SARS and MERS discovered restricted accessible examinations, with the greater part of these researching SARS. Clinical examinations in SARS were related with decreased mortality and intubation rates, yet the irretrospective, observational nature forestalls authoritative ends. The planning of organization during the early pinnacle viral replication stage (initial7-10days) gives off an impression of being significant in light of the fact that postponed treatment commencement with lopinavir/ritonavir had no impact on clinical results. Early reports of lopinavir/ritonavir for the treatment of COVID-19 are generally case reports and little review, non randomized companion considers, making it hard to learn the immediate treatment impact of lopinavir/ritonavir. Albeit deferred treatment commencement may somewhat clarify the insufficiency of lopinavir/ritonavir for treating COVID-19, as gathering investigation didn't discover shorter time to clinical improvement for patients who got treatment inside 12days. Albeit extra RCTs of lopinavir/ritonavir are continuous, the present information propose a constrained job for lopinavir/ritonavir in COVID-19treatment. The most normally utilized and examined lopinavir/ritonavir dosing routine for COVID-19 treatment is 400mg/100mg twice every day for upto 14days.[23] Given the critical medication tranquilize connections and potential unfavorable medication responses, cautious audit of corresponding meds and observing are required if this medication isused. Unfriendly impacts of lopinavir/ritonavir incorporate gastrointestinal pain, for example, sickness and looseness of the bowels (upto 28%) and hepatotoxicity (2%-10%).

In patients with COVID-19, these antagonistic impacts might be exacerbated by mix treatment or viral disease in light of the fact that roughly 20% to 30% of patients have raised transaminases at introduction with COVID-19. An ongoing RCT indicated around half of lopinavir/ritonavir patients encountered an antagonistic impact and 14% of patients stopped treatment because of gastrointestinal unfriendly impacts. Medication initiated transaminitis is of specific concern since it might worsen liver injury coming about because of COVID-19. Significantly, alanine transaminase rises are an avoidance rule in a few COVID-19 investigational preliminaries, implying that lopinavir/ritonavir prompted hepatotoxicity could confine patients capacity to get to these other drugs.[24]



Figure 3: Simplified representation of severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) viral life cycle and potential drug targets

Different Antiretrovirals

Different antiretrovirals, including protease inhibitors and integrase strand move inhibitors, were recognized by catalyst action screening as having SARS-CoV-2 action. In vitro cell models showed action of darunavir against SARS-CoV-2. There is no human clinical information in COVID-19 with these medications, yet a RCT of darunavir/cobicistatin China is underway.[24]

Umifenovir

Umifenovir (otherwise called Arbidol) is an all the more encouraging repurposed antiviral operator with a one of a kind instrument of activity focusing on the S-protein/ACE2 collaboration and hindering film combination of the viral envelope. The operator is as of now affirmed in Russia and China for the treatment and prophylaxis of flu and is of expanding enthusiasm for treating COVID-19 dependent on in vitro information recommending movement against SARS. The present portion of 200mg orally like clockwork for flu is being read for COVID-19 treatment (NCT04260594). Constrained clinical involvement in umifenovir for COVID-19 has been portrayed in China. An on randomized investigation of 67 patients with COVID-19 indicated that treatment with umifenovir for a middle span of 9 days was related with lower death rates (0% [0/36] versus 16% [5/31]) and higher release rates contrasted and patients who didn't get the agent.[25] This observational information can not build up the adequacy of umifenovir for COVID-19, yet continuous RCTs in China are further assessing this specialist.

Oseltamivir

Oseltamivir, a neuraminidase inhibitor affirmed for the treatment of flu, has no archived in vitro movement against SARSCoV-2. TheCOVID-19 flare-up in China at first happened during top flu periods of an enormous extent of patients got exact oseltamivir treatment until the revelation of SARS-CoV-2 as the reason for COVID-19. A few of the current clinical preliminaries incorporate oseltamivir in the examination gathering yet not as a proposed helpful mediation. This operator has no job in the administration of COVID-19 once flu has been excluded.[26]

Favipiravir

Favipiravir, recently known as T-705, is a prodrug of a purine nucleotide, favipiravir ribofuranosyl-5'-triphosphate. The dynamic operator represses the RNA polymerase, ending viral replication. A large portion of favipiravir's preclinical information are gotten from its flu and Ebola action; be that as it may, the specialist likewise showed expansive action against other RNA infections. Different dosing regimens have been proposed dependent on the sort of irresistible sign. Dosing varieties are likely because of the lower favipiravir EC50 values portrayed against flu contrasted and Ebola and SARS-CoV-2. Dosages at the higher finish of the dosing reach ought to be considered for the treatment of COVID-19. A stacking portion is suggested (2400mg to 3000mg each 12 hours× 2 dosages) trailed by an upkeep portion (1200mg to 1800mg at regular intervals). The half-life is around 5 hours. The specialist has a mellow unfavorable impact profile and is generally all around endured, in spite of the fact that the unfriendly occasion profile for higher-portion regimens is limited.[27]

Favipiravir is as of now accessible in Japan for the treatment of flu, however not accessible in the United States for clinical use. Constrained clinical experience has been accounted for supporting the utilization of favipiravir for COVID-19. This survey of proposed drugs is by need specific. An ongoing exhaustive survey directed by a division of the American Chemical Society examined logical information identified with helpful operators and antibodies in human coronaviruses since 2003, utilizing both distributed writing and licenses around the world. This examination revealed in excess of 130 licenses and in excess of 3000 potential little atom tranquilize applicants with potential movement against human coronaviruses. A similar investigation recognized in excess of 500 licenses for biologic operators with action against coronaviruses including remedial antibodies, cytokines, RNA treatments, and immunizations. Another preprint examination of SARS-CoV-2–human protein-protein connection maps recognized 332 high-certainty protein-protein cooperations, yielding 66 applicant druggable human proteins or host factors focused by either existing FDA-affirmed or investigational drugs. This huge measure of potential operators will ideally yield more competitor therapeutics in the race to discover compelling medicines or preventive procedures against COVID-19.[28]



Figure 4: Experimental treatment strategies attempt to interfere with different steps in the coronavirus replication cycle

Adjunctive Therapies

At present without demonstrated treatment for SARS-CoV-2, the foundation of care for patients with COVID-19 stays strong consideration, extending from indicative outpatient the executives of escalated care support. Be that as it may, 3 adjunctive treatments that warrant unique notice are corticosteroids, anticytokine or immunomodulatory operators, and immunoglobulin treatment.

Anticytokine or Immunomodulatory Agents

Monoclonal antibodies coordinated against key provocative cytokines or different parts of the inborn resistant reaction speak to another potential class of adjunctive treatments for COVID-19. The method of reasoning for their utilization is that the fundamental pathophysiology of noteworthy organ harm in the lungs and different organs is brought about by an intensified resistant reaction and cytokine discharge, or "cytokine storm." 79IL-6 seems, by all accounts, to be a key driver of this dysregulated aggravation dependent on early case arrangement from China. Along these lines, monoclonal antibodies againstIL-6 could hypothetically hose this procedure and improve clinical results. Tocilizumab, a monoclonal counter acting agent IL-6 receptor rival, is FDA affirmed to treat RA and cytokine discharge condition following illusory antigen receptor T-cell treatment. Given this experience, tocilizumab has been utilized in little arrangement of extreme COVID-19 cases with early reports of achievement. A report of 21 patients with COVID-19 demonstrated receipt of tocilizumab, 400 mg, was related with clinical improvement in 91% of patients as estimated by improved respiratory capacity, quick defervescence, and fruitful release, with most patients just accepting 1 portion. The absence of a comparator bunch restricts the understanding of the medication explicit impact and warrants alert until progressively thorough information are accessible. A few RCTs of tocilizumab, alone or in blend, inpatients with COVID-19 with extreme pneumonia are in progress in China (NCT04310228, ChiCTR200002976), and it is remembered for the present Chinese national treatment guidelines.[29]

Corticosteroids

The method of reasoning for the utilization of corticosteroids is to diminish the host incendiary reactions in the lungs, which may prompt intense lung injury and intense respiratory trouble disorder (ARDS). In any case, this advantage might be out weighed by unfavorable impacts, including deferred viral freedom and expanded danger of optional disease. Albeit direct proof for corticosteroids in COVID-19 is constrained, audits of results in other viral pneumonias are informational.

Table 1: Pharmacology of select proposed COVID-19 treatment

Agents	Target	Dose	Contraindications
Chloroquine Phosphate	Blockade of viral entry by inhibiting glycosylation receptors, proteolytic processing, and endosomal acidification. Additional immunomodulatory effects through inhibition of cytokine production, and liposomal activity in host cells.	500 mg by mouth every 12-24h ×5-10 days.	Hypersensitivity to chloroquine, 4-aminoquinoline compounds, or any component of formulation. Presence of retinal or visual field changes of any etiology
Hydrochloroquine sulphate	Same mechanism of action as chloroquine	400mg by mouth every 12h×1day, 200mg by mouth every 12h×4days.	Known hypersensitivity to hydrochloroquine, 4- aminoquinoline derivative, or any component of the formulation
Lopinavir/ritonavir	3CL protease	400mg/100mg by mouth every 12hr for upto 14days.	Co-administration with drugs highly dependent on CYP4504A. co-administration with potent CYP4503A inducers
Umifenovir	S protein/ACE2, membrane fusion inhibitor	200mg every 8 h by mouth 7-14 days.	Known hypersensitivity to umifenovir
Remdesivir	RNA polymerase inhibitor	200mg ×1, 100mg every 24 h IV infusion.	Exclusion criteria based on specific protocols
Favipiravir	RNA polymerase inhibitor	Doses vary based on indication, limited data available. Available as (not in the US) 200mg tablet.	Exclusion criteria based on specific protocols
Tocilizunab	IL-6 inhibition- reduction in cytokine strome	400mg IV or 8mg/kg × 1-2 doses. Second dose 8-12 h after first dose if inadequate response.	Known hypersensitivity to tocizunab or any component of the formulation. Caution in patients with neutropenia (<500 cells/µL)

Observational examinations in patients with SARS and MERS detailed no relationship of corticosteroids with improved endurance, yet showed a relationship with postponed viral freedom from the respiratory tract and blood and high paces of difficulties including hyperglycemia, psychosis, and a vascular corruption. Also, a 2019 meta examination of 10 observational investigations with 6548 patients with flu pneumonia found that corticosteroids were related with an expanded danger of mortality and a 2-crease higher danger of optional infections.[30]

Immunoglobulin Therapy

Another potential adjunctive treatment for COVID-19 is the utilization of gaining strength plasma or hyper safe immunoglobulins. The reason for this treatment is that antibodies from recouped patients may help with both free infection and contaminated cell resistant leeway. Recounted reports or conventions for gaining strength plasma have been accounted for as rescue treatment in SARS and MERS. A 2009 planned observational examination in 93 basically sick patients with H1N1 flu A, 20 of whom got improving plasma, exhibited that receipt of gaining strength plasma versus non receipt was related with a decrease in mortality Although current business immunoglobulin arrangements likely need defensive antibodies to SARS-CoV-2, this methodology warrants further wellbeing and viability preliminaries as the pool of patients who have recuperated from COVID-19 increments all around. To be sure, the primary revealed uncontrolled case arrangement of 5 fundamentally sick patients with COVID-19 treated with healing plasma in China was as of late published.[31] Also, a case arrangement of 3 patients with COVID-19 in Wuhan, China, treated with intravenous immunoglobulin at a portion of 0.3 to 0.5g/kg/d for 5 days was as of late published.[32] A far reaching survey of immunization examine for SARS-CoV-2 is past the extent of this audit.



Figure 5: Management of COVID-19

Preventions

Preventive procedures are centered around the disengagement of patients and cautious disease control, including suitable measures to be embraced during the determination and the arrangement of clinical consideration to a contaminated patient. For example, bead, contact, and airborne safeguards ought to be received during example assortment, and sputum acceptance ought to be maintained a strategic distance from[32].

- Avoid close contact with subjects experiencing intense respiratory diseases.
- Wash your hands every now and again, particularly after contact with tainted individuals or their condition.
- Avoid unprotected contact with homestead or wild creatures.
- People with manifestations of intense aviation route contamination should stay away, spread hacks or sniffles with dispensable tissues or garments and wash their hands.
- Strengthen, specifically, in crisis medication offices, the utilization of exacting cleanliness measures for the anticipation and control of diseases.
- Individuals that are invulnerable bargained ought to keep away from open social events.

CONCLUSION

The COVID-19 pandemic speaks to the best worldwide general wellbeing emergency of this age and, conceivably, since the pandemic flu episode of 1918. The speed and volume of clinical preliminaries propelled to examine potential treatments for COVID-19 feature both the need and capacity to deliver top notch proof even in the center of a pandemic. No treatments have been demonstrated viable to date.

REFERENCES

1. Fehr AR, Perlman S, Coronaviruses: an overview of their replication and pathogenesis, Methods in Molcular Biology, 1282, 2015, 1-23.
2. Lu R, Zhao X, Li J, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet, 395, 2020, 565-574.
3. Yin Y, Wunderink RG, MERS, SARS and other coronaviruses as causes of pneumonia. Respirology, 23, 2018, 130–137.
4. Francesco DG, Damiano P, Claudia M, Mario A, Vincenzo R, Nicola V, Lee S, Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. International Journal of Environmental Research and Public Health, 17, 2020, 2690.
5. Lei J, Kusov Y, Hilgenfeld R, Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. Antiviral Research, 149, 2018, 58–74.

6. Letko M, Marzi A, Munster V, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses, Nature Microbiology, 5, 2020, 562–569.
7. Pyle CJ, Uwadiae FI, Swieboda DP, Harker JA, Early IL-6 signalling promotes IL-27 dependent maturation of regulatory T cells in the lungs and resolution of viral immunopathology, PLOS Pathogen, 2017, 13.
8. Chen C, Zhang XR, Ju ZY, He WF, Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies, China journal of Chinese materia medica, 2020, 36.
9. Bennardo F, Buffone C, Giudice A. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws. Oral Oncology, 2020, 104659.
10. Rose JS, Interleukin-6 family cytokines, Cold Spring Harbor Perspectives in Biology, 2018, 10.
11. Lupia T, Scabini S, Mornese PS, Di PG, De R, Corcione S, 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge, Journal of Global Antimicrobial Resistance, 21, 2020, 22–27.
12. Stockman LJ, Bellamy R, Garner P, SARS: systematic review of treatment effects, PLOS Medicine, 3, 2006, 343.
13. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R, Effects of chloroquine on viral infections: an old drug against today's diseases, Lancet Infectious Dissease, 3, 2003, 722-727
14. Zhou D, Dai SM, Tong Q, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, Journal of Antimicrobial Chemotherapy, 2020, 114.
15. Yao X, Ye F, Zhang M, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus2 (SARS-CoV-2), Clinical Infectious Disease, 2020.
16. Lim HS, Im JS, Cho JY, Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by *Plasmodium vivax*, Antimicrobial Agents Chemotherapy, 53, 2009, 1468-1475.
17. Gautret P, Lagier JC, Parola P, Hydroxychloroquine and azithromycinasa treatment of COVID-19: results of an open-label non-randomized clinical trial, International Journal of Antimicrobial Agents, 2020.
18. Colson P, Rolain JM, Lagier JC, Brouqui P Raoult D, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, International Journal of Antimicrobial Agents, 2020.
19. Osadchy A, Ratnapalan T, Koren G, Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature, Journal of Rheumatology, 38, 2011, 2504-2508.
20. Arabi YM, Shalhoub S, Mandourah Y, Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study, Clinical Infectious Disease, 2019.
21. Altınbas S, Holmes JA, Altınbas A, Hepatitis C virus infection in pregnancy: an update, Gastroenterology Nursing, 43, 2020, 12-21.
22. De Wilde AH, Jochmans D, Posthuma CC, Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication incellculture, Antimicrob Agents Chemother, 58, 2014, 4875-4884.
23. Cao B, Wang Y, Wen D, A trial of lopinavir-ritonavirin adults hospitalized with severe COVID-19, New England Journal of Medicine, 2020.
24. Clinical Trials. Gov. Accessed March 18, 2020.
25. Wang Z, Yang B, Li Q, Wen L, Zhang R, Clinical Features of 69 cases with corona virus disease 2019 in Wuhan, China. Clinical Infectious Disease, 2020.
26. Wang D, Hu B, Hu C, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, Journal of American Medical Association, 2020.
27. Shiraki K, Daikoku T, Favipiravir, an anti-influenza drug against life-threatening RNA virus infections, Pharmacology and Therapeutics, 2020, 107512.
28. Gordon DE, Jang GM, Bouhaddou M, A SARS-CoV-2-human protein-protein interaction ma preveals drug targets and potential drug-repurposing, Bio Research xiv, 2020.
29. National Health Commission and State Administration of Traditional Chinese Medicine, Diagnosis and treatment protocol for novel corona virus pneumonia, 2020.
30. Arabi YM, Mandourah Y, Al-Hameed F, Saudi Critical Care Trial Group, Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome, American Journal of Respiratory Critical Care, 197, 2018, 757-767.
31. Shen C, Wang Z, Zhao F, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, Journal of American Medical Association 2020.
32. Cao W, Liu X, Bai T, High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019, Open Forum Infectious Disease, 2020.

Source of Support: Nil, **Conflict of Interest:** None.